New Onset Diabetes in Pancreatic Adenocarcinoma Does Not Correlate With Molecular Subtype.

IF 2 3区医学 Q3 ONCOLOGY

Journal of Surgical Oncology Pub Date : 2024-12-22 DOI:10.1002/jso.28044

Hannah E Trembath, Michelle E LaBella, Joseph F Kearney, Arthi Hariharan, Sandra Zarmer, Mariaelena Nabors, Ian McCabe, Ryan T Zhao, Michael Meyers, Hong Jin Kim, Jen Jen Yeh

{"title":"New Onset Diabetes in Pancreatic Adenocarcinoma Does Not Correlate With Molecular Subtype.","authors":"Hannah E Trembath, Michelle E LaBella, Joseph F Kearney, Arthi Hariharan, Sandra Zarmer, Mariaelena Nabors, Ian McCabe, Ryan T Zhao, Michael Meyers, Hong Jin Kim, Jen Jen Yeh","doi":"10.1002/jso.28044","DOIUrl":null,"url":null,"abstract":"Background and objectives: Studies show that new onset diabetes mellitus (DM) (NOD) predates the diagnosis of PDAC by up to 2 years. Two tumor-intrinsic molecular subtypes of PDAC that are prognostic and predictive of chemotherapy response have been described and validated. We hypothesize that patients with NOD may have different molecular subtypes and prognoses.Methods: This is a single-institution study of patients who underwent resection for PDAC from 2009 to 2022 with de-identified samples available for sequencing. Demographic and clinical factors were examined using bivariate and multivariate analysis.Results: A total of 97 patients met inclusion criteria: 70 with no history of DM, 11 with longstanding DM (> 2 years), and 16 with NOD. The demographics between groups were overall similar. After controlling for age, sex, race, BMI, and tobacco history, NOD was not a significant predictor of PDAC subtype. There were no survival differences between groups. Transcriptomic analysis suggests the upregulation of inflammatory and immune activation and regulation pathways in NOD.Conclusions: As continued interest in NOD and PDAC mounts, we are the first to examine if NOD may be associated with molecular subtypes and outcomes. Further investigation into the underlying pathophysiology of the NOD group is still needed.","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.28044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: Studies show that new onset diabetes mellitus (DM) (NOD) predates the diagnosis of PDAC by up to 2 years. Two tumor-intrinsic molecular subtypes of PDAC that are prognostic and predictive of chemotherapy response have been described and validated. We hypothesize that patients with NOD may have different molecular subtypes and prognoses.

Methods: This is a single-institution study of patients who underwent resection for PDAC from 2009 to 2022 with de-identified samples available for sequencing. Demographic and clinical factors were examined using bivariate and multivariate analysis.

Results: A total of 97 patients met inclusion criteria: 70 with no history of DM, 11 with longstanding DM (> 2 years), and 16 with NOD. The demographics between groups were overall similar. After controlling for age, sex, race, BMI, and tobacco history, NOD was not a significant predictor of PDAC subtype. There were no survival differences between groups. Transcriptomic analysis suggests the upregulation of inflammatory and immune activation and regulation pathways in NOD.

Conclusions: As continued interest in NOD and PDAC mounts, we are the first to examine if NOD may be associated with molecular subtypes and outcomes. Further investigation into the underlying pathophysiology of the NOD group is still needed.

查看原文本刊更多论文

胰腺腺癌新发糖尿病与分子亚型无关

背景和目的：研究表明，新发糖尿病（DM）（NOD）早于PDAC的诊断长达2年。两种肿瘤固有的PDAC分子亚型是化疗反应的预后和预测已经被描述和验证。我们假设NOD患者可能有不同的分子亚型和预后。方法：这是一项针对2009年至2022年接受PDAC切除术的患者的单机构研究，这些患者的去鉴定样本可用于测序。使用双变量和多变量分析检查人口统计学和临床因素。结果：共有97例患者符合纳入标准：70例无糖尿病病史，11例长期糖尿病（bbb - 2年），16例NOD。两组之间的人口统计数据总体上相似。在控制了年龄、性别、种族、BMI和吸烟史后，NOD不是PDAC亚型的显著预测因子。各组之间没有生存差异。转录组学分析表明NOD的炎症和免疫激活和调节途径上调。结论：随着对NOD和PDAC的持续关注，我们首次研究了NOD是否可能与分子亚型和结果相关。NOD组的病理生理机制仍需进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Surgical Oncology 医学-外科

CiteScore

4.70

自引率

4.00%

发文量

367

审稿时长

2 months

期刊介绍： The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.